| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 41 | 2024 | 456 | 10.980 |
Why?
|
| Buprenorphine | 20 | 2024 | 181 | 8.230 |
Why?
|
| Substance-Related Disorders | 42 | 2023 | 687 | 7.270 |
Why?
|
| Opiate Substitution Treatment | 30 | 2024 | 187 | 5.600 |
Why?
|
| Substance Abuse Treatment Centers | 28 | 2020 | 104 | 4.220 |
Why?
|
| Methadone | 19 | 2024 | 127 | 3.160 |
Why?
|
| Analgesics, Opioid | 18 | 2024 | 483 | 2.980 |
Why?
|
| Drug Overdose | 7 | 2024 | 126 | 2.720 |
Why?
|
| Crime | 12 | 2017 | 50 | 2.530 |
Why?
|
| Prisoners | 7 | 2024 | 151 | 2.030 |
Why?
|
| Adult | 73 | 2024 | 15670 | 1.900 |
Why?
|
| California | 29 | 2019 | 161 | 1.660 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 6 | 2021 | 25 | 1.650 |
Why?
|
| Qualitative Research | 10 | 2024 | 618 | 1.630 |
Why?
|
| Humans | 110 | 2024 | 59393 | 1.530 |
Why?
|
| Female | 77 | 2024 | 30711 | 1.380 |
Why?
|
| Narcotic Antagonists | 7 | 2024 | 121 | 1.330 |
Why?
|
| Male | 71 | 2024 | 27730 | 1.320 |
Why?
|
| Health Services Accessibility | 7 | 2023 | 527 | 1.260 |
Why?
|
| Adult Survivors of Child Adverse Events | 2 | 2019 | 9 | 1.240 |
Why?
|
| Criminal Law | 4 | 2023 | 70 | 1.170 |
Why?
|
| Young Adult | 26 | 2024 | 4269 | 1.150 |
Why?
|
| Massachusetts | 11 | 2024 | 2019 | 1.150 |
Why?
|
| Veterans | 4 | 2022 | 727 | 1.130 |
Why?
|
| Health Status Disparities | 3 | 2017 | 137 | 1.110 |
Why?
|
| Naltrexone | 5 | 2024 | 77 | 1.090 |
Why?
|
| Veterans Health | 2 | 2018 | 158 | 1.070 |
Why?
|
| Alcoholism | 5 | 2017 | 310 | 1.040 |
Why?
|
| Middle Aged | 39 | 2024 | 16299 | 0.980 |
Why?
|
| Public Health | 3 | 2023 | 176 | 0.960 |
Why?
|
| Sex Factors | 12 | 2024 | 935 | 0.950 |
Why?
|
| Allostasis | 1 | 2024 | 9 | 0.930 |
Why?
|
| Mental Health Services | 7 | 2023 | 269 | 0.910 |
Why?
|
| Mental Recall | 1 | 2024 | 88 | 0.890 |
Why?
|
| Prisons | 8 | 2024 | 105 | 0.890 |
Why?
|
| Delayed-Action Preparations | 1 | 2024 | 111 | 0.880 |
Why?
|
| Longitudinal Studies | 9 | 2024 | 1187 | 0.870 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 84 | 0.850 |
Why?
|
| Community Health Services | 2 | 2018 | 120 | 0.850 |
Why?
|
| Narcotics | 6 | 2017 | 50 | 0.850 |
Why?
|
| Community Mental Health Services | 6 | 2014 | 88 | 0.850 |
Why?
|
| Cannabis | 2 | 2021 | 51 | 0.840 |
Why?
|
| Criminals | 3 | 2013 | 53 | 0.820 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2017 | 12 | 0.820 |
Why?
|
| Psoriasis | 2 | 2020 | 50 | 0.810 |
Why?
|
| United States | 15 | 2024 | 7422 | 0.760 |
Why?
|
| Recidivism | 1 | 2022 | 26 | 0.740 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 2337 | 0.730 |
Why?
|
| Health Personnel | 3 | 2021 | 342 | 0.710 |
Why?
|
| Adolescent | 23 | 2021 | 5833 | 0.710 |
Why?
|
| Caregivers | 2 | 2020 | 231 | 0.690 |
Why?
|
| Prediabetic State | 1 | 2020 | 51 | 0.660 |
Why?
|
| Conduct Disorder | 1 | 2019 | 24 | 0.650 |
Why?
|
| Patients | 1 | 2020 | 103 | 0.650 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 515 | 0.640 |
Why?
|
| Cocaine-Related Disorders | 5 | 2017 | 82 | 0.600 |
Why?
|
| Anxiety Disorders | 2 | 2019 | 186 | 0.600 |
Why?
|
| Methamphetamine | 6 | 2017 | 22 | 0.600 |
Why?
|
| Musculoskeletal Pain | 1 | 2018 | 27 | 0.590 |
Why?
|
| Complementary Therapies | 1 | 2018 | 56 | 0.580 |
Why?
|
| Law Enforcement | 4 | 2017 | 24 | 0.560 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 35 | 0.540 |
Why?
|
| Treatment Outcome | 23 | 2021 | 5307 | 0.540 |
Why?
|
| Life Change Events | 1 | 2017 | 65 | 0.530 |
Why?
|
| Dementia | 2 | 2016 | 248 | 0.520 |
Why?
|
| Chronic Pain | 1 | 2018 | 134 | 0.520 |
Why?
|
| Personal Autonomy | 1 | 2016 | 68 | 0.510 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 330 | 0.510 |
Why?
|
| Medicaid | 1 | 2020 | 353 | 0.510 |
Why?
|
| Aged | 14 | 2024 | 13399 | 0.500 |
Why?
|
| Mothers | 5 | 2014 | 257 | 0.480 |
Why?
|
| Health Services Needs and Demand | 3 | 2016 | 203 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 454 | 0.480 |
Why?
|
| Mental Health | 1 | 2018 | 336 | 0.470 |
Why?
|
| Homes for the Aged | 1 | 2016 | 157 | 0.470 |
Why?
|
| Heroin Dependence | 3 | 2017 | 22 | 0.450 |
Why?
|
| Pandemics | 4 | 2022 | 617 | 0.440 |
Why?
|
| Patient Safety | 1 | 2016 | 237 | 0.440 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2019 | 116 | 0.430 |
Why?
|
| Social Environment | 1 | 2014 | 91 | 0.430 |
Why?
|
| Safety | 1 | 2014 | 142 | 0.430 |
Why?
|
| Butterflies | 2 | 2024 | 32 | 0.420 |
Why?
|
| Perception | 1 | 2014 | 168 | 0.420 |
Why?
|
| Program Evaluation | 6 | 2010 | 470 | 0.410 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2016 | 74 | 0.410 |
Why?
|
| Residence Characteristics | 1 | 2014 | 215 | 0.410 |
Why?
|
| Mental Disorders | 3 | 2015 | 720 | 0.390 |
Why?
|
| Policy | 2 | 2021 | 48 | 0.390 |
Why?
|
| Employment | 2 | 2009 | 124 | 0.370 |
Why?
|
| Prevalence | 3 | 2020 | 1253 | 0.370 |
Why?
|
| Nursing Homes | 1 | 2016 | 661 | 0.350 |
Why?
|
| Recurrence | 6 | 2012 | 602 | 0.340 |
Why?
|
| Cohort Studies | 10 | 2024 | 2371 | 0.340 |
Why?
|
| Prospective Studies | 9 | 2019 | 3066 | 0.330 |
Why?
|
| Patient Dropouts | 2 | 2011 | 47 | 0.330 |
Why?
|
| Patient Compliance | 5 | 2012 | 349 | 0.320 |
Why?
|
| Mandatory Programs | 1 | 2008 | 17 | 0.310 |
Why?
|
| Drug Users | 1 | 2008 | 28 | 0.300 |
Why?
|
| Databases as Topic | 1 | 2008 | 52 | 0.290 |
Why?
|
| Interviews as Topic | 4 | 2024 | 484 | 0.290 |
Why?
|
| Skin | 3 | 2020 | 357 | 0.280 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2379 | 0.280 |
Why?
|
| Data Collection | 2 | 2006 | 371 | 0.280 |
Why?
|
| Age Factors | 6 | 2016 | 1503 | 0.280 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 191 | 0.270 |
Why?
|
| Sex Distribution | 2 | 2017 | 244 | 0.270 |
Why?
|
| Schizophrenia | 2 | 2022 | 243 | 0.260 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 742 | 0.260 |
Why?
|
| Comorbidity | 3 | 2021 | 1077 | 0.260 |
Why?
|
| HIV Infections | 5 | 2016 | 913 | 0.260 |
Why?
|
| Drug and Narcotic Control | 4 | 2007 | 28 | 0.260 |
Why?
|
| Indians, North American | 1 | 2006 | 27 | 0.260 |
Why?
|
| Depression | 2 | 2021 | 829 | 0.250 |
Why?
|
| Gender Identity | 2 | 2023 | 62 | 0.250 |
Why?
|
| Time Factors | 8 | 2018 | 3614 | 0.240 |
Why?
|
| Research Design | 1 | 2008 | 555 | 0.240 |
Why?
|
| Wings, Animal | 1 | 2024 | 19 | 0.230 |
Why?
|
| Pigmentation | 1 | 2024 | 25 | 0.230 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2015 | 79 | 0.230 |
Why?
|
| Poetry as Topic | 1 | 2004 | 3 | 0.230 |
Why?
|
| Age of Onset | 3 | 2017 | 170 | 0.220 |
Why?
|
| Aphasia | 1 | 2024 | 42 | 0.210 |
Why?
|
| Income | 1 | 2024 | 157 | 0.210 |
Why?
|
| Privacy | 1 | 2023 | 12 | 0.210 |
Why?
|
| Intellectual Disability | 2 | 2016 | 159 | 0.210 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 210 | 0.210 |
Why?
|
| Social Stigma | 1 | 2023 | 64 | 0.200 |
Why?
|
| Inflammation | 2 | 2020 | 1099 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 2 | 2017 | 63 | 0.200 |
Why?
|
| Risk Factors | 4 | 2018 | 5016 | 0.200 |
Why?
|
| Grounded Theory | 1 | 2022 | 17 | 0.200 |
Why?
|
| Health Services Research | 2 | 2023 | 266 | 0.200 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 152 | 0.200 |
Why?
|
| Prescription Drug Diversion | 1 | 2022 | 7 | 0.200 |
Why?
|
| Inpatients | 2 | 2021 | 292 | 0.190 |
Why?
|
| Rural Population | 1 | 2023 | 188 | 0.190 |
Why?
|
| Mood Disorders | 2 | 2019 | 69 | 0.190 |
Why?
|
| Acute Pain | 1 | 2021 | 17 | 0.180 |
Why?
|
| Adaptation, Psychological | 3 | 2016 | 259 | 0.180 |
Why?
|
| Secondary Prevention | 3 | 2013 | 151 | 0.180 |
Why?
|
| Legislation, Drug | 1 | 2020 | 17 | 0.180 |
Why?
|
| Data Anonymization | 1 | 2020 | 1 | 0.180 |
Why?
|
| Feeding and Eating Disorders | 1 | 2021 | 49 | 0.170 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2516 | 0.170 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 28 | 0.170 |
Why?
|
| Risk-Taking | 3 | 2016 | 158 | 0.170 |
Why?
|
| Personality Disorders | 1 | 2019 | 19 | 0.170 |
Why?
|
| Focus Groups | 3 | 2016 | 288 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 413 | 0.160 |
Why?
|
| Health Equity | 1 | 2020 | 42 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 52 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 309 | 0.150 |
Why?
|
| Autistic Disorder | 1 | 2021 | 145 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 246 | 0.150 |
Why?
|
| Sensory Receptor Cells | 1 | 2018 | 17 | 0.150 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 271 | 0.150 |
Why?
|
| Stroke | 2 | 2024 | 1126 | 0.150 |
Why?
|
| Anxiety | 1 | 2021 | 387 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 297 | 0.140 |
Why?
|
| Logistic Models | 3 | 2017 | 1234 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 551 | 0.140 |
Why?
|
| Financing, Government | 1 | 2017 | 30 | 0.140 |
Why?
|
| England | 1 | 2016 | 24 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 789 | 0.130 |
Why?
|
| Risk Management | 1 | 2016 | 38 | 0.130 |
Why?
|
| Behavioral Symptoms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 41 | 0.130 |
Why?
|
| Insulin | 1 | 2020 | 673 | 0.130 |
Why?
|
| Motivation | 2 | 2009 | 274 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2020 | 941 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2049 | 0.130 |
Why?
|
| Environment | 1 | 2016 | 118 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3230 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 203 | 0.130 |
Why?
|
| Telemedicine | 1 | 2020 | 308 | 0.120 |
Why?
|
| Health Surveys | 1 | 2017 | 298 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 31 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1479 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 93 | 0.120 |
Why?
|
| Analgesics | 1 | 2016 | 96 | 0.120 |
Why?
|
| Quality of Life | 2 | 2022 | 1171 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2017 | 283 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 381 | 0.120 |
Why?
|
| Self Report | 2 | 2021 | 359 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2016 | 143 | 0.120 |
Why?
|
| Population Density | 1 | 2014 | 11 | 0.120 |
Why?
|
| Olfactory Perception | 1 | 2014 | 3 | 0.120 |
Why?
|
| Glucose | 1 | 2017 | 445 | 0.110 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 11 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 519 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 43 | 0.110 |
Why?
|
| Smell | 1 | 2014 | 26 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 13 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2014 | 48 | 0.110 |
Why?
|
| Pain Management | 1 | 2016 | 146 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 168 | 0.110 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 212 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 426 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 634 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 241 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2014 | 156 | 0.110 |
Why?
|
| Climacteric | 1 | 2012 | 4 | 0.100 |
Why?
|
| Animals | 5 | 2024 | 19643 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 149 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 110 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 292 | 0.100 |
Why?
|
| Interview, Psychological | 1 | 2012 | 73 | 0.100 |
Why?
|
| Child | 6 | 2021 | 4188 | 0.100 |
Why?
|
| Parents | 1 | 2016 | 366 | 0.100 |
Why?
|
| Tobacco Use Cessation | 1 | 2012 | 29 | 0.100 |
Why?
|
| Disease Progression | 1 | 2016 | 1119 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 725 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6098 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2008 | 278 | 0.090 |
Why?
|
| Mice | 2 | 2020 | 10288 | 0.080 |
Why?
|
| Crack Cocaine | 1 | 2008 | 7 | 0.070 |
Why?
|
| Utilization Review | 1 | 2008 | 31 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 5112 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 364 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 826 | 0.070 |
Why?
|
| Exercise | 1 | 2014 | 883 | 0.070 |
Why?
|
| Public Health Administration | 1 | 2006 | 22 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2008 | 148 | 0.070 |
Why?
|
| Forensic Psychiatry | 1 | 2006 | 51 | 0.070 |
Why?
|
| Ethics, Clinical | 1 | 2006 | 3 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2012 | 914 | 0.060 |
Why?
|
| Confidentiality | 1 | 2006 | 52 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 415 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 1491 | 0.060 |
Why?
|
| Harm Reduction | 1 | 2024 | 29 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2004 | 43 | 0.060 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 2 | 0.050 |
Why?
|
| Marijuana Abuse | 2 | 2017 | 20 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2024 | 117 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2024 | 75 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 1792 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2023 | 54 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 137 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 224 | 0.050 |
Why?
|
| Language | 1 | 2024 | 133 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2023 | 161 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 122 | 0.050 |
Why?
|
| DNA Transposable Elements | 1 | 2022 | 127 | 0.050 |
Why?
|
| State Government | 1 | 2021 | 29 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 60 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 350 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1134 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 776 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2022 | 298 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 65 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 327 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 319 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 1238 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 144 | 0.040 |
Why?
|
| Drosophila | 1 | 2022 | 421 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 453 | 0.040 |
Why?
|
| TRPA1 Cation Channel | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hypertension | 1 | 2024 | 570 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2018 | 8 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2018 | 10 | 0.040 |
Why?
|
| Denervation | 1 | 2018 | 17 | 0.040 |
Why?
|
| Diterpenes | 1 | 2018 | 19 | 0.040 |
Why?
|
| Substance P | 1 | 2018 | 44 | 0.040 |
Why?
|
| TRPV Cation Channels | 1 | 2018 | 18 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 599 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 59 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 205 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2011 | 589 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 75 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2016 | 58 | 0.030 |
Why?
|
| Crime Victims | 1 | 2017 | 32 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 192 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 189 | 0.030 |
Why?
|
| Homeostasis | 1 | 2017 | 346 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2015 | 61 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2015 | 88 | 0.030 |
Why?
|
| Seizures | 1 | 2015 | 112 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 2211 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2014 | 1957 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 2015 | 125 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 355 | 0.030 |
Why?
|
| Pediatrics | 1 | 2016 | 241 | 0.030 |
Why?
|
| British Columbia | 1 | 2012 | 4 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 103 | 0.020 |
Why?
|
| New York | 1 | 2012 | 134 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 284 | 0.020 |
Why?
|
| Prescription Drug Misuse | 1 | 2011 | 20 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 169 | 0.020 |
Why?
|
| China | 1 | 2011 | 133 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1282 | 0.020 |
Why?
|
| Reward | 1 | 2011 | 83 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 144 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 804 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 379 | 0.020 |
Why?
|
| Aging | 1 | 2015 | 709 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2008 | 27 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 64 | 0.020 |
Why?
|
| Substance Abuse Detection | 1 | 2007 | 44 | 0.020 |
Why?
|
| Episode of Care | 1 | 2006 | 8 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2006 | 93 | 0.020 |
Why?
|
| Patient Admission | 1 | 2006 | 184 | 0.010 |
Why?
|
| Residential Treatment | 1 | 2004 | 30 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2004 | 303 | 0.010 |
Why?
|